Goldman Sachs' report highlights stocks with high consensus ROE, ranking Pfizer Inc. 27th. Market dynamics are shifting due to interest rate changes, impacting economic conditions and stock performance. Despite Pfizer's expiring patents, its future depends on new drug development.